XN Checkout – Buy
We tipped this supplier of EPOS solutions to pubs and restaurants at 141.5p in February's Growth Company Investor and, clearly, we are delighted with the subsequent trading and share price performance.
XN Checkout came to AIM last June with a £5m funding at 98p that cleared its debts. Since then it has placed shares at 99p and 155p, raising another £7.2m. Figures for the year to December revealed pre-tax profits topping £1.7m and a £3.9m PBT swing from losses of £2.2m, as sales rose 28% to £18.5m. Chief executive Ed Dayan said a slew of orders in the second half helped the company move into the black last year. Encouragingly, there was record growth in the hospitality division, where sales surged from £3.6m to £6.5m. The company has also announced its third acquisition since the end of December – it is paying a maximum £1.05m for XNA, a South African firm that distributes its products in South Africa. These include casino industry products; XNC had already made a promising debut in the casino gaming systems field, having delivered touch screen roulette systems to firms like Gala and Stanley Leisure. Following the stellar numbers, house broker and adviser Daniel Stewart has upgraded profit forecasts for 2005 from £3.1m to £5m, giving earnings of 17.9p a share and a forward rating of 15.6. We remain buyers.- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
